SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Wheatley Adam K.)
 

Sökning: WFRF:(Wheatley Adam K.) > Progress in vaccine...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00009405naa a2200841 4500
001oai:DiVA.org:umu-212064
003SwePub
008230718s2023 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:152377118
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-2120642 URI
0247 a https://doi.org/10.1111/nyas.149752 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1523771182 URI
040 a (SwePub)umud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Cable, Jenniferu PhD Science Writer, NY, United States4 aut
2451 0a Progress in vaccine development for infectious diseases :b a Keystone Symposia report
264 1b John Wiley & Sons,c 2023
338 a print2 rdacarrier
520 a The COVID-19 pandemic has taught us many things, among the most important of which is that vaccines are one of the cornerstones of public health that help make modern longevity possible. While several different vaccines have been successful at stemming the morbidity and mortality associated with various infectious diseases, many pathogens/diseases remain recalcitrant to the development of effective vaccination. Recent advances in vaccine technology, immunology, structural biology, and other fields may yet yield insight that will address these diseases; they may also help improve societies' preparedness for future pandemics. On June 1-4, 2022, experts in vaccinology from academia, industry, and government convened for the Keystone symposium "Progress in Vaccine Development for Infectious Diseases" to discuss state-of-the-art technologies, recent advancements in understanding vaccine-mediated immunity, and new aspects of antigen design to aid vaccine effectiveness.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Infektionsmedicin0 (SwePub)302092 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Infectious Medicine0 (SwePub)302092 hsv//eng
653 a antigen design
653 a mRNA vaccines
653 a structural vaccinology
653 a vaccine delivery
653 a vaccine hesitancy
653 a vaccines
7001 a Graham, Barney S.u Morehouse School of Medicine, GA, Atlanta, United States4 aut
7001 a Koup, Richard A.u Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, MD, Bethesda, United States4 aut
7001 a Seder, Robert A.u Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, MD, Bethesda, United States4 aut
7001 a Karikó, Katalinu Karolinska Institutet4 aut
7001 a Pardi, Norbertu Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, PA, Philadelphia, United States4 aut
7001 a Barouch, Dan H.u Harvard Medical School, MA, Boston, United States4 aut
7001 a Sharma, Bhawnau Gilead Sciences, CA, Foster City, United States4 aut
7001 a Rauch, Susanneu CureVac AG, Tübingen, Germany4 aut
7001 a Nachbagauer, Raffaelu Department of Microbiology, Icahn School of Medicine at Mount Sinai, NY, United States; Moderna, MA, Cambridge, United States4 aut
7001 a Forsell, Mattias N. E.u Umeå universitet,Institutionen för klinisk mikrobiologi4 aut0 (Swepub:umu)mafo0173
7001 a Schotsaert, Michaelu Department of Microbiology, Icahn School of Medicine at Mount Sinai, NY, United States; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai New York, NY, United States4 aut
7001 a Ellebedy, Ali H.u Department of Pathology and Immunology; Center for Vaccines and Immunity to Microbial Pathogens; and The Andrew M. and Jane M. Bursky Center for Human Immunology & Immunotherapy Programs, Washington University School of Medicine, St. Louis, Missouri, USA4 aut
7001 a Loré, Karinu Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden4 aut
7001 a Irvine, Darrell J.u Koch Institute for Integrative Cancer Research; Department of Biological Engineering; and Department of Materials Science and Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA; Consortium for HIV/AIDS Vaccine Development (CHAVD), Scripps Research Institute, La Jolla, CA, United States; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, MA, Cambridge, United States4 aut
7001 a Pilkington, Emilyu Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, VIC, Melbourne, Australia; Department of Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, VIC, Melbourne, Australia4 aut
7001 a Tahtinen, Siriu Genentech, CA, South San Francisco, United States4 aut
7001 a Thompson, Elizabeth A.u Department of Medicine, Johns Hopkins University School of Medicine, MD, Baltimore, United States4 aut
7001 a Feraoun, Yanisu Inserm, Center for Immunology of Viral, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-SaclayFontenay-aux-Roses, CEA, France4 aut
7001 a King, Neil P.u Department of Biochemistry and Institute for Protein Design, University of Washington, WA, Seattle, United States4 aut
7001 a Saunders, Kevinu Human Vaccine Institute, Duke University, NC, Durham, United States4 aut
7001 a Alter, Galitu Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, MA, Cambridge, United States4 aut
7001 a Moin, Syed M.u Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, MD, Bethesda, United States4 aut
7001 a Sliepen, Kwintenu Department of Medical Microbiology, University of Amsterdam, Amsterdam, Netherlands4 aut
7001 a Karlsson Hedestam, Gunilla B.u Karolinska Institutet4 aut
7001 a Wardemann, Heddau Division of B Cell Immunology, German Cancer Research Center, Heidelberg, Germany4 aut
7001 a Pulendran, Baliu Institute for Immunity, Transplantation and Infection; Department of Pathology; and Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford University, Stanford, California, USA4 aut
7001 a Doria-Rose, Nicole A.u Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, MD, Bethesda, United States4 aut
7001 a He, Wan-Tingu Consortium for HIV/AIDS Vaccine Development (CHAVD), Scripps Research Institute, La Jolla, CA, United States; Department of Immunology and Microbiology and IAVI Neutralizing Antibody Center, Scripps Research Institute, La Jolla, CA, United States4 aut
7001 a Juno, Jennifer A.u Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, VIC, Melbourne, Australia4 aut
7001 a Ataca, Silau Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, MD, Bethesda, United States4 aut
7001 a Wheatley, Adam K.u Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, VIC, Melbourne, Australia4 aut
7001 a McLellan, Jason S.u Department of Molecular Biosciences, University of Texas at Austin, TX, Austin, United States4 aut
7001 a Walker, Laura M.u Adimab, LLC, NH, United States4 aut
7001 a Lederhofer, Juliau Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, MD, Bethesda, United States4 aut
7001 a Lindesmith, Lisa C.u Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States4 aut
7001 a Wille, Holgeru Centre for Prions and Protein Folding Diseases and Department of Biochemistry, University of Alberta, AB, Edmonton, Canada4 aut
7001 a Hotez, Peter J.u Texas Children's Center for Vaccine Development, Departments of Pediatrics and Molecular Virology & Microbiology, National School of Tropical Medicine, Baylor College of Medicine, TX, Houston, United States; James A Baker III Institute for Public Policy, Rice University, TX, Houston, United States; Department of Biology, Baylor University, TX, Waco, United States; Hagler Institute for Advanced Study and Scowcroft Institute of International Affairs, Bush School of Government and Public Service, Texas A&M University, College Station, TX, United States4 aut
7001 a Bekker, Linda-Gailu Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa4 aut
7102 a PhD Science Writer, NY, United Statesb Morehouse School of Medicine, GA, Atlanta, United States4 org
7730 t Annals of the New York Academy of Sciencesd : John Wiley & Sonsg 1524:1, s. 65-86q 1524:1<65-86x 0077-8923x 1749-6632
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-212064
8564 8u https://doi.org/10.1111/nyas.14975
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:152377118

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy